The Cooper Companies, Inc. $COO Stock Sold by Boston Trust Walden Corp

Posted by Brenda Bartman on Nov 7th, 2026

Boston Trust Walden Corp lowered its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO – Free Report) by 76.5% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 69,786 shares of the medical device company’s stock after selling 226,916 shares during the period. Boston Trust Walden Corp’s holdings in Cooper Companies were worth $3,945,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. bought a new stake in Cooper Companies in the 2nd quarter valued at about $1,077,762,000. Generation Investment Management LLP bought a new stake in shares of Cooper Companies during the 2nd quarter worth approximately $356,304,000. Jupiter Topco LLC bought a new stake in shares of Cooper Companies during the 2nd quarter worth approximately $305,074,000. JANA Partners Management LP boosted its position in shares of Cooper Companies by 0.5% during the 2nd quarter. JANA Partners Management LP now owns 3,582,480 shares of the medical device company’s stock worth $256,900,000 after acquiring an additional 17,322 shares in the last quarter. Finally, Wellington Management Group LLP boosted its position in shares of Cooper Companies by 3.1% during the 2nd quarter. Wellington Management Group LLP now owns 3,468,951 shares of the medical device company’s stock worth $248,758,000 after acquiring an additional 103,044 shares in the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Mizuho set a $75.00 price objective on shares of Cooper Companies and gave the company an “outperform” rating in a research note on Thursday, September 10th. Barclays raised shares of Cooper Companies to a “hold” rating in a research note on Wednesday, October 7th. Citigroup reiterated a “neutral” rating and issued a $60.00 price target (down from $80.00) on shares of Cooper Companies in a research note on Thursday, September 10th. Piper Sandler reissued a “neutral” rating on shares of Cooper Companies in a report on Thursday, October 15th. Finally, William Blair lowered Cooper Companies from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 10th. Four investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $68.60.

Get Our Latest Analysis on COO

Insider Activity at Cooper Companies

In related news, Director Lawrence Kurzius bought 10,000 shares of the business’s stock in a transaction on Wednesday, September 16th. The shares were purchased at an average price of $54.93 per share, with a total value of $549,300.00. Following the completion of the purchase, the director owned 31,099 shares of the company’s stock, valued at $1,708,268.07. This represents a 47.40% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Walter Rosebrough, Jr. bought 3,000 shares of Cooper Companies stock in a transaction on Monday, September 14th. The shares were bought at an average price of $54.29 per share, for a total transaction of $162,870.00. Following the acquisition, the director owned 20,000 shares of the company’s stock, valued at approximately $1,085,800. The trade was a 17.65% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders bought 34,701 shares of company stock valued at $1,880,039. Insiders own 2.08% of the company’s stock.

Cooper Companies Trading Down 1.8%

Shares of NASDAQ:COO traded down $1.15 during trading hours on Friday, hitting $62.36. 2,059,749 shares of the company’s stock traded hands, compared to its average volume of 3,311,420. The firm has a market capitalization of $11.86 billion, a P/E ratio of 21.28, a price-to-earnings-growth ratio of 2.41 and a beta of 0.83. The business has a fifty day moving average price of $59.20 and a 200-day moving average price of $68.61. The Cooper Companies, Inc. has a 1 year low of $51.01 and a 1 year high of $89.83. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.22 and a quick ratio of 0.73.

Cooper Companies (NASDAQ:COO – Get Free Report) last announced its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%. The company had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.10 billion. During the same period in the previous year, the business earned $0.49 EPS. Cooper Companies’s revenue for the quarter was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Equities analysts expect that The Cooper Companies, Inc. will post 4.53 earnings per share for the current year.

Cooper Companies announced that its Board of Directors has initiated a share buyback plan on Wednesday, September 9th that permits the company to buy back $3 billion in shares. This repurchase authorization permits the medical device company to purchase up to 22.7% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s leadership believes its stock is undervalued.

Cooper Companies Company Profile

(Free Report)

CooperCompanies is a global medical device company that develops, manufactures and markets products for vision care and women’s health. The company operates through two primary business segments: CooperVision and CooperSurgical.

CooperVision provides contact lenses and related technologies, including products designed for myopia management, astigmatism, presbyopia and other vision-correction needs. Its portfolio includes daily disposable, reusable and specialty contact lenses sold through eye-care professionals and distributors.

CooperSurgical develops products and services for fertility and women’s health.